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Sulnmary 
Human lymphoblastoid cells transiently expressing the hemagglutinin (HA)  glycoprotein of 
influenza virus are rapidly and efficiently recognized by CD4 + HA-specific T lymphocytes. This 
endogenous presentation pathway is sensitive to chloroquine and is therefore likely related to 
the classical  class II major histocompatibility complex (MHC) exogenous pathway of antigen 
presentation.  In this study we have examined a series  of transport-defective HA mutants.  We 
correlate the intracellular fate of the native antigen with its presentation characteristics. We have 
found that the native antigen must enter the secretory pathway since a cytosolic form is not 
presented. However, surface expression and normal trafficking through the Golgi apparatus are 
not required for efficient presentation.  Instead, escape of native antigen from the endoplasmic 
reticulum appears to be both necessary and sufficient for gaining access to a compartment where 
antigen is processed and binds class  II MHC  molecules. 
T 
he last  decade has  seen major advances in our under- 
standing of the pathways by which protein antigens are 
processed to peptide fragments and presented by class I and 
II MHC molecules. The major features of these two pathways 
have been described (for reviews see references 1-4). A cur- 
rent paradigm implicates access of the antigen to specific in- 
tracellular  compartments  as  being  crucial  in  determining 
whether it is presented in association with MHC class I or 
II molecules. Newly synthesized proteins (5), or intact pro- 
tein molecules artificially introduced to the cytosolic com- 
partment (6),  are processed and efficiently presented in as- 
sociation with class I MHC molecules (7, 8). Proteins entering 
the endosomal compartment are processed and preferentially 
charge class  II MHC  molecules (5). 
This division between processing pathways is not abso- 
lute, and apparent exceptions have been documented. For ex- 
ample, specialized cells in the thymus and spleen may be able 
to process and present preformed exogenous proteins in as- 
sociation with class  I MHC  molecules, albeit with a low 
efficiency (9-12).  Additionally, newly synthesized cytosolic 
and secretory proteins have been reported to charge class II 
molecules (13-20). A critical issue in interpreting these findings 
is whether these results represent antigen-processing events 
in novel compartments, e.g., MHC class II charging in the 
endoplasmic reticulum (ER), 1 or instead, reflect alternative 
mechanisms of targeting antigen to previously described pro- 
cessing and presentation compartments, e.g., the late endo- 
some/lysosome. 
Recently, we described the recognition of the influenza 
A/Japan/305/57  hemagglutinin (HA) glycoprotein by human 
class II-restricted T lymphocytes (21). In this report we have 
examined in further detail the pathway by which this HA 
is presented to these CD4 + class II-restricted T cells. In con- 
trast to earlier studies in the murine system (5), these lym- 
phocytes efficiently recognize newly synthesized HA acutely 
expressed using a viral expression vector. Using a series  of 
transport-defective HA mutants, we have found that newly 
synthesized A/Japan/57 HA must gain access to the ER but 
does not need to transit to the cell surface, or transit through 
the Golgi stacks to be presented to the T  cells.  These data 
suggest that there is a mechanism by which proteins present 
in the secretory pathway can be sampled from a transitional 
element between the ER and Golgi stacks, or an early Golgi 
compartment,  and be delivered to an endosomal compart- 
ment for processing and presentation by class II MHC mole- 
1Abbreviations  used  in  this  paper:  Elk,  endoplasmic  reticulum;  HA, 
hemagglutinin; wt,  wild type. 
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secretory compartments to the site of class II MHC charging 
is described,  and implications  of this pathway for tolerance 
and  autoimmunity  are discussed. 
Materials and Methods 
Cell Lines.  V1  is  a  CD4 + MHC  class  II-restricted human 
cytolytic T cell clone. Its specificity  has been mapped for HAs of 
the H2 subtype (which include A/Japan/305/57),  and the peptide 
VKILPKDRWTQH, which corresponds to amino acids 129-140 
of the HA protein, in association with HLA-DRw11 (21). This 
clone was isolated as described in detail elsewhere (22) and is main- 
rained by weekly restimulation with irradiated (2,600 tad) aUogeneic 
PBMC (isolated using Histopaque 1077; Sigma Chemical Co., St. 
Louis,  MO)  +  OKT3 (anti-CD3 mAb, 6.25 ng/ml final; Ortho 
Diagnostic Systems,  Inc., Westwood,  MA) in RPMI 1640  sup- 
plemented to 10% with heat-inactivated FCS, 4 mM glutamine, 
and human rib2 (20 U/ml final; Biosource International, CamariUo, 
CA).  TBLCL is an EBV-transformed B lymphoblastoid cell line 
isolated from the same individual as V1. It was transformed using 
standard procedures (23) and is maintained by serial passage every 
3-4 d in RPMI 1640, 10% heat-inactivated FCS, 4 mM glutamine. 
This medium was used for all experiments unless otherwise noted. 
HA Mutants.  All of the HA constructs described below have 
been cloned into the vaccinia virus thymidine kinase gene by ho- 
mologous recombination and are expressed under the control of 
the P7.5 early/late viral promoter. Details of the construction of 
recombinant vaccinia viruses and their growth and purification are 
described elsewhere (24-26).  Because  vaccinia virus does not in- 
corporate influenza proteins into its virion, the only HA protein 
available is that synthesized in the target cell during infection. Al- 
though crude virus stocks could contain some HA protein from 
cellular debris, demonstration of the requirement for de novo HA 
synthesis was verified by testing sucrose gradient-purified virions 
(with identical results) and UV-inactivated  virus preparations (nega- 
tive). HA refers  to wild-type (wt) HA of the H2 subtype from 
A/Japan/305/57;  the vaccinia virus carrying this gene was a kind 
gift from Dr. Bernard Moss (National Institute of Allergy and In- 
fectious Disease).  Signal-minus HA (HA-S-) has been engineered 
such that the 15-amino acid leader sequence NH2 terminal of the 
signal cleavage site is replaced by amino acid residues  MELG (27). 
Anchor HA HA-A- is a form of HA generated by deleting nu- 
cleotides coding for the 38 amino acids comprising the transmem- 
brane region and cytoplasmic tail and replacing them with a sequence 
coding  for the  short,  relatively hydrophilic  sequence PPPGSR- 
HDKIH (27).  HA164 was generated by cutting the HA gene at 
the coding junction between the transmembrane and cytoplasmic 
domains and blunt-end ligating ClaI linkers (28).  This alters the 
reading frame, creating a novel cytoplasmic tail of the residues IDG- 
SAGSAYDYKSFYN  (wt tail sequence is NGSI.QCRICI). HAC67S 
is identical to wt, with the exception of a single mutation leading 
to an amino acid substitution at position 67 of the mature protein 
(position 82 from methionine initiation)  (29).  A cysteine residue 
involved in an intramolecular disulfide bond is replaced by serine. 
HAAR1 was created by cutting the wt HA cDNA at two EcoRI 
sites to form an in-frame deletion mutant (30). This removes amino 
acids 248-409 to form a protein of 398 amino acids. HA-EEKKMP 
was designed to be an ER retention mutant and was constructed 
by engineering the COOH-terminal six amino acids of the adeno- 
virus E3/19K glycoprotein onto the cytoplasmic tail of HA. Previous 
studies have demonstrated the role of these amino acids  for the 
retention of adenovirus E3/19K and other transmembrane glyco- 
proteins, to which this sequence has been transplanted  (31,  32). 
Briefly, wt HA was removed from the plasmid pMTHA (26) by 
digesting with HindlII and NdeI. NdeI cuts within the 3' coding 
region  for the  cytoplasmic tail.  The oligonucleotides  (5'  to Y) 
TAGAAGAGAAAAAGATGCCTTGAGC  and  TCAAGGCAT- 
CTTTTTCTCTTC were synthesized using standard automated 
procedures, annealed, phosphorylated, and ligated to the HA frag- 
ment generated above and to pSCll.3 (26) (digested with HindlII 
and SaclI, and dephosphorylated with calf intestinal phosphatase). 
These oligos were chosen so as to finish  coding the wt HA se- 
quence, then code for the amino acids EEKKMP, and finally a stop 
codon. The finished construction was verified by sequencing. Vac- 
cinia recombinants were generated as with the other mutants, plaque 
purified,  grown  as  high-titer  stocks,  and  sucrose  gradient  was 
purified. Note that the T  cell epitope (129-140)  is retained in all 
of these mutants. 
Infections.  TBLCL were washed and then resuspended in serum- 
free RPMI 1640 and infected with the recombinant vaccinia viruses 
at 50 PFU/cell for 10 min on ice, then 60 min at 37~  Cells were 
then washed and resuspended in medium with serum and incubated 
at 37~  The time of incubation before and during the assay varied 
between assays and is noted in individual results. 
Antibodies.  3CSBB9 is a polyclonal rabbit anti-HA antiserum. 
This Ab works efficiently for immunoprecipitation and recognizes 
both the wt and the mutant HA molecules. Fc125 is a mouse anti- 
HA mAb and is used in the form of hybridoma culture superua- 
tant. It does not recognize the HAAR 1 construction by immuno- 
precipitation, so it was not used for those studies.  The secondary 
Ab used for flow cytometry is a FITC-conjugated goat Ab to mu- 
fine IgG2b (Southern Biotechnology Associates, Birmingham, AL) 
that  shows very low nonspecific binding in flow cytometry. 
CTL Killing Assay.  TBLCL were labeled at 106 cells/ml for 
2-3  h  at  37~  with  -100  mCi/ml  SlCr  sodium  chromate 
(DuPont-NEN,  Wilmington,  DE).  Before the  assay, they were 
washed three times to remove released 51Cr and resuspended  at 0.5 
or 1  x  105 cells/ml. Target cells were plated at 100 gtl/well in 96- 
well plates, and an equal volume of clone (experimental), medium 
(spontaneous release), or 2% Triton X-100 (maximum release) was 
added. Final E/T ratios are indicated in the figure legends. Plates 
were spun, 2-3 rain at 50g and then incubated at 37~  with 10% 
CO2. 100/zl/well of superuatant was harvested and counted in a 
gamma  counter  (Pharmacia/LKB,  Uppsala,  Sweden).  Percent 
specific killing was calculated by the following formula: 100 x  (ex- 
perimental  -  spontaneous)/(maximum release  -  spontaneous). 
All groups were performed in quadruplicate.  SD was usually 2-3%, 
and the spontaneous release  was routinely  10--15%, 
Flow Cytometry.  TBLCL were infected as noted above and in- 
cubated for various times (as indicated in the figure legends) before 
staining.  Cells were then plated at 2.5-5  x  10S/well in 96-well 
plates and maintained at 4~  An equal volume of Fc125 culture 
supernatant diluted 1:10 with medium was then added to each well. 
Cells were incubated 30 min and then washed three times. Cells 
were resuspended in the secondary Ab diluted 1:20 with medium 
and incubated a further 30 min. Cells were then washed again three 
times and resuspended in 1% buffered formalin phosphate. Cells 
were analyzed on FACScan |  using Consort 30 and Lysys software 
(Becton Dickinson & Co.,  Mountain  View,  CA). 
Metabolic Labeling and Immunoprecipitation.  Cells were pulse ra- 
diolabeled in MEM (minus cysteine/methionine)  supplemented with 
5% heat-inactivated FCS, 4 mM glutamine, 100 mCi/ml [3SS]me- 
thionine (EXPRE3sS3sS  protein labeling mix; DuPont-NEN)  for 
30 min at 37~  Cells were washed and then chased in serum- 
containing medium supplemented with I mM methionine and 0.2 
1022  Hemagglutinin  Recognition by CD4 + Cells mM cysteine at 37~  for the times indicated. Cells were then washed 
and  quick  frozen with  liquid  nitrogen.  Cells  were  thawed  and 
resuspended in lysis buffer containing 0.5%  NP-40 and the pro- 
tease inhibitor PMSF (0.2 mM final) for 30 rain on ice. Nuclei were 
spun out and lysates  precleared twice with protein A-Sepharose 
(Pharmacia Fine Chemicals, Piscataway, NJ). Anti-HA Ab was added 
to the lysates, followed by protein A-Sepharose. Precipitated com- 
plexes were washed three times and eluted into 0.2 M citric acid/so- 
dium phosphate buffer (pH 6.2)  +  0.2%  SDS. Samples were ex- 
posed to 1 mU Endo H  (Oxford Glycosystems, Foster City, CA) 
or 7 mU Endo D  (Sigma Chemical Co.), or mock digested over- 
night (2 d for Endo D  experiments) at 37~  Reducing (2-ME) 
sample buffer was then added, and samples were boiled before 10% 
(5% stacking gel) SDS-PAGE.  Gels were then fixed, impregnated 
with fluorograph (Fluorohance; Research Products International, 
Rochester, NY), dried,  and exposed to X-ray film at  -80~  be- 
fore development. 
I~sults 
CD4 § T  Cell Recogniaon of N~ly Synthesized HA.  We 
have examined the presentation of the influenza A/Japan/57 
HA  glycoprotein by human  B  lymphoblastoid  cells  (I.CL) 
to CD4 §  MHC  class II-restricted T  lymphocytes.  As pre- 
viously  reported  (21),  a  clonal  population  of MHC  class 
II-restricted  T  cells  recognizes  EBV-transformed  lympho- 
blastoid cells treated with either infectious influenza virions, 
isolated HA protein, or a synthetic peptide spanning amino 
acids  126-145  (minimal peptide  is  129-140)  of the  mature 
HA protein in association with HLA-DRwll.  In addition, 
we found that the human T  lymphocytes efficiently recog- 
nize  newly synthesized  HA protein  expressed by a  recom- 
binant  vaccinia vector (Fig.  1).  This  observation is in con- 
trast with our earlier observations of murine CD4 + T  cells 
where B cells poorly present newly synthesized HA expressed 
in  these  APC  (5). 
New viral protein synthesis was required for sensitization 
of cells expressing  HA by infection  with  the  recombinant 
Figure  2.  Target  cell sensitization by vaccinia  HA requires de novo pro- 
tein  synthesis, sxCr-labeled TBLCL were infected with  the  A/Japan/ 
305/57 influenza virus or an HA-expressing recombinant vaccinia  vector 
(wt HA) and subsequently  incubated at 37~  for 3 h in the absence (stippled 
bars) or presence (filled bars)  of 10 -5 M emetine. Both emetine-treated and 
untreated cells were incubated with the CTL done VI in the presence 
of 10 -6 M emetine for 2 h at 37~  at the indicated E/T ratios. Values 
are the percent of control lysis of infected target cells in the absence of 
any emetine treatment during preincubation or assay.  Control lysis values 
(defined as 100%) for A/Japan/305/57-infected  and vaccinia-expressing 
wt  HA-infected calls were 63  and  30%,  respectively, at  an E/T  cell 
ratio of 5:1. 
vaccinia virus.  As Fig.  2  demonstrates,  the presence  of the 
protein synthesis inhibitor emetine at the initiation of infec- 
tion  virtually  abolishes  recognition.  However,  target  cells 
treated with influenza virion preparations (containing virion- 
associated HA protein,  unlike the vaccinia virus) efficiently 
processed and presented  HA in the presence of the protein 
synthesis inhibitor.  These data also imply that in these cells 
processing  and presentation  of exogenous  HA may not  re- 
quire newly synthesized MHC  class II molecules.  Presenta- 
tion of newly synthesized HA expressed after vaccinia virus 
infection was also sensitive to the weak base chloroquine,  as 
shown in Fig.  3.  As expected, chloroquine had no effect on 
A/Jap/'30S/S7  m 
~lx, e - 
wtHA- 
vacdnla- 
UV-A/Jap/30~- 
HA protein- 
''  '1'0'  '  '  '20'  '  '  '~'''  '~'''  '$0'  '  '  '60'  '  '  '710  '''  '80 
% st~ane l~s 
Figure  1.  MHC class II-restricted T cell recognition of exogenous and 
endogenous HA. TBLCL were infected with influenza viruses (A/Japan/ 
305/57 [B/Lee]), the recombinant vacdnia expressing the A/Japan/305/57 
HA gene (wt HA), vaccinia alone, or treated either with noninfectious 
UV-irradiated A/Japan/305/57 virus (UVA/JAP/57),  or with detergent- 
solubilized HA (HA trrotein)  at a final  concentration of 5/~g/ml. HA-specific 
DRwll-restricted  CTL (V1) were incubated with sICr-labeled  target cells 
for 2.5 h at an E/T ratio of 5:1 as described in Materials and Methods. 
Figure  3.  Chloroquine inhibits presentation of newly synthesized HA. 
TBLCL were preincubated for 30 rain in the absence (stippled  bars)  or pres- 
ence (filled  bars) of 150 pM chloroquine and subsequently infected with 
vaccinia  virus expressing  wt HA (wt HA), or treated with UV-inactivated 
A/Japan/305/57,  the HA 126-145 synthetic peptide, or left untreated. 
The targets were 51Cr-labded for 3 h at 37~  before a 3-h incubation 
with the CTL clone VI. The chloroquine was absent or present at 150 
/zM until incubation with the CTL was commenced, at which point its 
concentration was decreased to 10 #M.  The E/T ratio was 20:1. 
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Presentation of Transport-defective HA Mutants.  Processing 
and presentation of newly synthesized HA in these lympho- 
blastoid cells could reflect MHC class II charging via a cyto- 
solic  or  an Elk processing event  and  subsequent  Dlkw11 
charging in the ER.  Alternatively, processing could occur 
in a late endosome/lysosome compartment after cell surface 
expression and subsequent internalization of the HA, as sug- 
gested by the chloroquine sensitivity of  presentation. To fur- 
ther explore possible presentation pathways and to better define 
the intracellular  site of  processing, we have examined the pro- 
cessing and presentation of a series of transport-defective HA 
mutants to the Dlkwll-restricted T  cells. Acute expression 
of these mutants from recombinant vaccinia virus vectors al- 
lowed us to determine the kinetics and relative efficiency of 
presentation,  parameters that are more difficult to assess when 
studying a constitutively expressed  antigen. 
As noted above, newly synthesized HA might be presented 
in association with MHC class II molecules through a cyto- 
solic processing  mechanism analogous to MHC class I pre- 
sentation (5, 10, 20, 33), or by fragmentation of HA derived 
from the secretory pathway but targeted to a conventional 
class II processing compartment, e.g., the lysosome, through 
endocytosis of cell surface HA. To discriminate between these 
two pathways, we examined the presentation of two HA mu- 
tants, HA-S-  and HS-A-.  The HA-S-  was engineered so 
as not to  encode the  NH2-terminal signal peptide of the 
A/Japan/305/57 HA polypeptide. This HA mutant remains 
cytosolic and is degraded very quickly in the cytosol (27). 
The HA-A-  mutant was similarly engineered by deleting 
the 3' region of the HA cDNA encoding the hydrophobic 
transmembrane  and hydrophilic cytoplasmic tail regions. Cells 
expressing  this mutant secrete a glycosylated product into 
the medium that can easily be detected by immunoprecipita- 
tion (27; and D. J. Kittlesen, unpublished observation). As 
seen in Fig. 4, LCL cells infected with the vaccinia virus recom- 
wtHA 
HA-A. 
HA-S- 
vaccinla  II 
'"s ....  io  is  i~  ~  ~  ........  3s  ~  is 
% specific lysis 
Figure 4.  Recognition  of a secreted, anchor-minus  HA but not of a 
signal-minus cytolytic form. TBLCL were infected with  vaccinia 
virus-expressing  wt HA, anchor-minus  HA (HA-A-),  signal-minus  HA 
(HA-S-), or vaccinia  alone. Targets  were slCr labeled overnight  at room 
temperature  before  incubation  for 2 h at 37~  and then  3 h with the CTL 
clone VI. The E/T ratio was 10:1. 
Figure  5.  The kinetics  of conversion  of wt and HA164 to Endo H re- 
sistance. TBLCL  were infected  with vaccinia  virus expressing  wt HA (a) 
or HA164 (b) and metabolically  labeled as described in Materials and 
Methods. A 30-min pulse radiolabeling  was initiated  3 h after  infection. 
Chase times are as follows:  0 rain (lanes I and 2), 30 min (Lanes  3 and 
4), 60 min (lanes 5 and 6), 90 min (lanes 7 and 8), and 120 min (lanes 
9 and 10). Odd-numbered  lanes are with Endo  H treatment;  even-numbered 
lanes were  mock  treated.  Open  arrows  indicate  immature  core  glycosylated 
forms  and the filled  arrows  indicate  mature  molecules  with  complex  oligosac- 
charides. The positions of molecular  weight markers are indicated. The 
band with a Mr of 45,000 is contaminating  actin. 
binant expressing  HA-S- are not recognized by the T  cells. 
This construction is functional and makes a translation product 
that is processed  and efficiently presented to CD8 + MHC 
class I-restricted T  cells (M. Sweetser  and T. J. B., unpub- 
lished  observation).  The  failure of the  HA-S-  to  charge 
DRw11 argues against the idea of the cytoplasm as an efficient 
source of peptide for presentation of this unstable cytosolic 
HA to CD4 + T  cells. In contrast, cells infected with the 
recombinants expressing  the HA-A-  gene product are rec- 
ognized as efficiently as wt HA (Fig. 4), implying that tar- 
geting to a class II processing compartment does not require 
anchoring of the glycoprotein into the cell's lipid bilayer and 
is not dependent on the presence of the intracytoplasmic HA 
tail.  These data raised  the possibility that cell surface  HA 
expression may not be necessary for MHC class II charging, 
and that a compartment between the Elk and cell surface might 
be the site of HA processing and presentation in association 
with Dlkw11. 
To better define this putative compartment, a series of HA 
mutants that are delayed or blocked in their egress from the 
Elk and that differ in their susceptibility to intracellular pro- 
teolysis  were  examined  for  recognition  by  the  Dlkw11- 
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Figure  6.  Flow cytometry comparison of wt HA and HA164. TBLCL 
were infected with the HA-expressing vaccinia viruses as indicated.  Cells 
were  subsequently  stained  and  analyzed  as  described  in  Materials  and 
Methods.  The time points indicate hours after initiation of infection. The 
filled area indicates fluorescence with the secondary Ab alone; the open 
area indicates  fluorescence with the primary and  secondary  antibodies. 
Figure  7,  Endo H sensitivity and degradation of HAC67S and HAAR1. 
TBLCL were infected  with  vaccinia vires expressing  HAC67S  (a)  or 
HAAR1 (b) and then metab.olically labeled as described in Materials and 
Methods.  The 30-min pulse was initiated 3 h after infection.  Chase times 
are as follows: 0 rain (lanes 1 and 2),  2 h  (lanes 3 and  4),  4 h  (lanes 5 
and 6), 6 h (lanes 7 and 8), and 8 h (lanes 9 and 10). Odd-numbered lanes 
are with Endo H treatment; even-numbered lanes were mock treated. The 
positions of molecular weight markers are indicated. The band with a Mr 
of 45,000  is contaminating actin. 
Table  1.  Presentation Kinetics of wt and Mutant  HA  Molecules 
Exp.  Time  E/T  wt  HA  HAC67S  HA164  HA-AP.1  Vaccinia 
h 
3.5-6.5 
5.5-8.5 
7.5-10.5 
2  3.5-7 
6.5-10 
9.5-13 
10:1  40  17  41  3  ND 
10:1  45  38  44  7  ND 
10:1  49  49  51  10  0 
wt  HA  HAC67S  HA-EEKKMP  HA-AR1  Untreated  HA  126-145 
15:1  67  15  71  7  0  74 
7:1  60  14  64  4  1  66 
2:1  47  10  51  5  1  50 
15:1  63  42  65  12  0  61 
7:1  55  38  11  58  0  57 
2:1  42  25  41  7  0  43 
15:1  70  58  66  18  0  60 
7:1  61  53  59  15  0  56 
2:1  45  40  43  11  0  39 
APC infected with recombinant  vaccinia viruses expressing  various  HA forms, treated  with HA 126-145  peptide,  infected  with vaccinia alone,  or 
left untreated (as indicated),  were incubated  with specific CTL for the time periods indicated  (postinfection).  Numbers indicate percent  specific lysis. 
Experiments  were performed  as in Fig.  7. 
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Time  E:T  -  Chloroquine  +  Chloroquine 
h 
4-7.5 
9.5-13 
15:1  22  3 
7:1  16  3 
2:1  9  2 
15:1  59  18 
7:1  46  12 
2:1  25  8 
APC infected  with recombinant vaccinia  viruses expressing HAC67S were 
incubated with specific CTL for time periods indicated (postinfection). 
Numbers indicate percent specific  lysis. Experiments were performed as 
in Fig. 3. 
restricted T  cells.  Included among these mutants is HA164, 
which has an altered cytoplasmic tail composed of 16 novel 
residues. This mutant is defective in its transit to the cell sur- 
face and may accumulate in a post-Golgi compartment (28). 
Fig. 5 shows a pulse-chase analysis of the acquisition of resis- 
tance to Endo H  by wt HA and the HA164 mutant in LCL 
cells.  Both wt HA (Fig.  5 a) and the HA164 mutant  (Fig. 
5 b) rapidly acquire resistance to Endo H, although HA164 
is slightly delayed (by 30-60 rain) in this conversion in the 
human LCL. When we examined cell surface expression of 
HA164 late  in infection  (6 h) by flow cytometry (Fig.  6), 
we found that the level of  cell surface HA in the HA164 mu- 
tant was substantially reduced compared with wt HA. The 
diminished cell surface expression of HA164, in spite of rapid 
acquisition of Endo H  resistance, is consistent with our ear- 
lier data on expression of HA164 in epithelial cells, suggesting 
that this mutant is significantly delayed in a post-Golgi com- 
partment during its transit to the cell surface [28]. Although, 
from our data,  we cannot formally rule out the possibility 
that  this  mutant  is  rapidly  internalized. 
When we examined CD4 § T  cell recognition of HA164, 
we found that target cells expressing this mutant were rec- 
ognized with the same efficiency and kinetics  as targets ex  o 
Figure 9.  Pulse-chase  analysis of HA-EEKKMP vs. wt HA. TBLCL 
were infected with vaccinia  virus expressing HA-EEKKMP  or wt HA and 
then metabolically  labeled as described  in Materials and Methods. The 30- 
rain pulse was initiated 3 h after infection. Chase times are as follows: 
0 min (lanes I and 2), 30 min (lanes 3 and 4), 1 h (lanes 5 and 6), 2 h 
(lanes 7 and 8), 4 h (lanes 9 and 10), and 8 h (lanes 11  and 12). Even- 
numbered lanes are with Endo H treatment; odd-numbered lanes were 
mock treated. Open arrows indicate immature core glycosylated  forms, 
and the filled arrows indicate mature molecules with complex oligosac- 
charides. The positions of molecular weight markers are indicated. 
pressing wt  HA (Table  1,  Exp.  1).  The rapid  and efficient 
processing and presentation of HA164, despite low cell sur- 
face expression,  reinforced the view that  internalization  of 
cell surface HA into an endosomal/lysosomal compartment 
might not be the pathway for processing and presentation 
of newly synthesized HA,  and  that  processing was  occur- 
ring  deeper  within  the cell. 
The ER has been proposed as a  site of proteolytic frag- 
mentation of newly synthesized secretory proteins,  as well 
as the site of charging of MHC class II molecules by the liber- 
ated peptides (17).  To explore the proximal secretory pathway 
as a site of HA processing and charging of DRw11,  we ex- 
amined  the  presentation  of three  HA  mutants:  HAC67S, 
8O 
70- 
60- 
~0-  i  i 
10- 
O. 
wt HA  HAC675  HA-~Lql  HA-EEKKMP  none  HA 126-145 
Figure 8.  The kinetics of presentation ofwt and mutant HAs. TBLCL 
were infected with  recombinant vaccinia viruses expressing the various 
forms of HA, treated with the HA 126-145 synthetic peptide, or left un- 
treated (as indicated). Cells were incubated for either 3.5 h (filled Mrs), 
6.5 h (striped bars), or 9.5 h (open bars) before a 3-h incubation with the 
CTL clone V1. An E/T ratio of 15:1 was used. 
Figure  10.  Endo  D sensitivity of wt and mutant HAs. TBLCL were 
infected with vaccinia virus expressing wt HA (lanes 1 and 2), HAC67S 
(lanes 3 and 4), or HAAR1 (lanes 5 and 6), and metabolically labeled as 
described in Materials and Methods. A 30-rain pulse and 30-min chase 
was initiated 2 h after infection. Odd-numbered lanes are with Endo D 
treatment; even-numbered  lanes were mock treated. Open arrows indicate 
immature core glycosylated  forms and the filled arrows indicate mature 
molecules with complex  oligosaccharides.  The positions of molecular weight 
markers are indicated. The band with a Mr of 45,000 is contaminating 
actin. 
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acid substitution in a site outside of the HA 129-140 epitope 
(serine for cysteine at position 67 in the mature protein). This 
mutant is unable to form a critical intramolecular disulfide 
bond necessary for stable HA trimer formation (29). As the 
pulse-chase analysis in Fig. 7 a shows, this molecule retains 
its Endo H  sensitivity throughout the period of the chase, 
suggesting that this molecule is retained in a premedial Golgi 
compartment. In addition, the HAC67S molecule is extremely 
stable. It is still detectable in the Endo H-sensitive form after 
8 h of chase and is slowly degraded in LCL cells with a half- 
life of 4-6 h (Fig. 7 a and D. J. Kittlesen, unpublished obser- 
vation). As expected, this mutant does not transit to the cell 
surface and is not detectable on infected cells by flow cytom- 
etry (data not shown). When we examined HAC67S recog- 
nition by HA 129-140-reactive T  cells, we found efficient 
presentation, albeit with somewhat delayed kinetics relative 
to wt HA (Fig.  8).  As with wt HA,  presentation of this 
mutant is also chloroquine sensitive (Table 2). These results 
implied that egress of the A/Japan/57 HA molecule through 
the secretory pathway is not required for its processing and 
charging of MHC class II molecules, and raised the possi- 
bility that MHC class II molecules might be charged in the 
ER by HA peptides derived from ER proteolysis. Our studies 
with the HA-EEKKMP and HAAR1 mutants do not sup- 
port this view. 
In an effort to examine the EtL as an antigen processing 
compartment for HA, we generated an ER retention mu- 
tant, referred to in this report as HA-EEKKMP. While KDEL 
retention sequences have been shown to be responsible for 
the retention of soluble ER proteins (reviewed in reference 
34),  this signal does not function for transmembrane pro- 
teins with their COOH termini located in the cytosol [35]. 
Instead,  type 1 transmembrane proteins utilize a different 
COOH-terminal signal for ER retention. The best charac- 
terized of these is that of the adenovirus E3/19k protein (31). 
The presence of two lysine residues at positions  -3 and -4 
(or  -5) from the COOH terminus has been demonstrated 
on numerous resident ER proteins and has been shown to 
be sufficient to retain other normally nonretained proteins 
when engineered onto their COOH termini (32). We chose 
therefore to express a form of wt HA containing the last six 
amino adds (-EEKKMP) of the adenovirus 5 E3/19k pro- 
tein. As shown in Fig. 9,  this molecule is in fact strongly 
retained relative to wt HA. However, leakage can be detected 
as a small pool of Endo H-resistant molecules detected at 
late chase times. Not surprisingly then, surface expression 
can be detected by flow cytometry and is *25%  of wt at 
9 h postinfection (not shown). This leak-through of proteins 
containing a retention sequence has been previously demon- 
strated, and was suggested to be a characteristic of the in- 
dividual protein or of different cell types used for expression 
(35, 36). This molecule is presented as well as wt HA (Fig. 
8 and Table  1).  Although ER proteolysis and charging of 
class II MHC could account for the efficient recognition of 
the HA-EEKKMP mutant by T cells, the mutant did egress 
from the ER. Therefore, processing of HA in a post-ER corn- 
partment remained a possibility.  We were able to test the 
contribution of ER processing using HAAR1, a mutant that 
fortuitously  is  retained  even  more  efficiently than  HA- 
EEKKMP. 
The HAAR1 mutant was generated by a large in-frame 
deletion of the sequences encoding residues 248-409 of the 
A/Japan/57 HA (30). This mutant retains the HA 129-140 
site recognized by the CD4 + T  cells.  When expressed in 
LCL, the truncated polypeptide is core glycosylated but does 
not mature to an Endo H-resistant form in pulse-chase ex- 
periments (Fig.  7  b).  Furthermore, the protein is rapidly 
degraded (with a half-life of •2  h) in a chloroquine-resistant 
manner, implying that it is susceptible to proteolysis in the 
ER-linked salvage/intermediate compartment (Fig. 7 b, and 
D. J. Kittlesen, unpublished observations). When tested for 
CD4 + T cell recognition, this mutant polypeptide was only 
poorly processed and presented (Fig. 8 and Table 1). While 
recognition was poor relative to wt HA, at later time points 
its recognition was detectable (up to 26% of wt; Table 1), 
indicating that this HA deletion mutant can charge class II 
MHC, but does so inefficiently. 
The difference in presentation between the two HA mu- 
tants that remain intracellular (HAC67S and HAAR1) may 
be explained by differences in their ability to escape from the 
ER and progress further along the secretory pathway. The 
enzyme Endo D can be used to distinguish these molecules. 
This enzyme recognizes and cleaves oligosaccharides of the 
structure (Man)s(GlcNAc)2 (37).  Trimming of oligosaccha- 
rides to this level is accomplished by a-mannosidase I, pre- 
sumably acting in the cis- or medial-Golgi compartment (38) 
and is, therefore, a marker for this compartment. Fig. 10 shows 
the susceptibility of these molecules to this enzyme. HAC67S 
(and an immature form of the wt HA) are recognized and 
trimmed by this  enzyme. Approximately one-half of the 
HAC67S is in an Endo D-recognizable form with doublet 
formation (Fig.  10, lane 3); while none of the HAAtL1 was 
recognized and remains a single species (Fig. 10, lane 5). There- 
fore, HAC67S, unlike the HAAR1, has likely progressed fur- 
ther through the secretory pathway and been modified in the 
Golgi compartment by ol-mannosidase 1. 
Discussion 
In this report we have examined the pathway by which 
the newly synthesized A/Japan/57 influenza virus HA gly- 
coprotein is processed and presented in association with MHC 
class II molecules in human APC. We have found that pro- 
cessing and presentation of the HA requires translocation of 
the HA glycoprotein into the ER, but transit of the HA gly- 
coprotein through the secretory pathway to the cell surface 
is not required for recognition of the processed protein by 
CD4 + T  lymphocytes. 
Two intracellular compartments, the cytosol and the late 
endosome/lysosome, have been implicated as major sites of 
antigen processing for presentation to T  lymphocytes. Al- 
though the cytosol is a major site of peptide formation for 
charging of MHC class I molecules, its role as a source of 
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We (7) and others (39) have previously provided evidence that 
proteins localized to the cytoplasm are inefficiently  processed 
and presented in association with MHC class II molecules, 
while other investigators have reported presentation of newly 
synthesized cytosolic proteins to CD4 § T cells (14, 16, 20). 
In the present report, the failure of the cytosolic signal-minus 
A/JAPAN/57 HA (Fig. 4) to be presented to HLA-DRw11- 
restricted T lymphocytes supports the view that, for this HA 
at least, localization of the HA polypeptide in the cytoplasm 
does not lead to MHC class II charging. 
Although wt influenza HA does not efficiently cycle from 
the cell surface into the cell (40), we initially considered cy- 
cling of cell surface HA into an endosomal/lysosomal pro- 
cessing compartment as the likely mechanism for the pro- 
cessing and presentation of the newly synthesized HA. Our 
experimental observations, however, did not substantiate this 
view. Notably, we found that the anchor-minus secreted form 
of HA, and the HA164 and HA-EEKKMP mutants, which 
appear to be delayed in transport to the cell surface, are rec- 
ognized by the HA 129-140-reactive T  cells with efficien- 
cies and kinetics comparable to wt HA. None of these forms 
of HA would be expected to cycle into an endosomal pro- 
cessing compartment from the cell surface with the efficiency 
of wt HA. More importantly, the HAC67S mutant, which 
does not transit to the cell surface and does not acquire resis- 
tance to Endo H, is also processed and presented in associa- 
tion with MHC class II molecules. This latter finding is in- 
compatible with HA transit to the cell surface as a necessary 
requirement for HA processing and presentation. 
Based on studies with ER-retained proteins,  Weiss  and 
Bogen (39) have proposed that the ER is a site of antigen 
processing and charging of the MHC class II molecules. Our 
data on the recognition of HAC67S by CD4 + T  cells are 
consistent  with  this  concept,  but  our  findings with  the 
HAAR1 mutant are not. Both HAC67S and HAAR1 retain 
the 129-140 HA site. Both HA products remain in an Endo- 
H-sensitive state in lymphoblastoid target cells. The HAC67S 
mutant is relatively stable  and is degraded with a half-life 
of ~4-6 h. The HAAR1 mutant is unstable and has a half- 
life of ,,o2 h. This pattern of Endo H  sensitivity and rapid 
degradation of the HAAR1 mutant (which is insensitive to 
treatment of the cells with 50/zM chloroquine; D. J. Kittle- 
sen, unpublished observation) are consistent with HAAR1 
proteolysis in the ER (41).  If proteolytic fragmentation in 
the ER were an important source of peptides for MHC class 
II charging, then the unstable HAAR1 mutant should be 
readily processed and presented. It is not, even at late times 
after expression of the mutant protein in the target cells (Fig. 
8).  Rather, MHC class II charging and T  cell recognition 
correlate more directly with HA stability in the ER, with 
the stable  wt HA being most efficiently processed. 
One explanation for the difference in the presentation of 
HAC67S and HAAR1 is that the stable HAC67S can transit 
from the ER to a compartment where it can be processed 
and presented in association with MHC class II molecules, 
while the unstable HAAR1 is primarily retained in the ER 
and degraded there. Consistent with this view, we have found 
that HAC67S, but not the HAAR1, acquires Endo D sensi- 
tivity by 90 min postsynthesis in target cells (Fig.  10). Since 
Endo D  sensitivity is believed to be acquired during glyco- 
protein transit into an early Golgi compartment (37,  38), 
HAC67S could transit further than HAAR1, where it can 
gain access to the MHC class II processing pathway. One 
attractive hypothesis consistent with our data is that proteins 
entering this ER to Golgi intermediate, or early Golgi, com- 
partment are directly targeted to a late endosome/lysosome 
for fragmentation and subsequent charging of MHC class 
II molecules. Proteins have been engineered containing the 
KDEL ER retention sequence for soluble lumenal proteins 
and have been shown to be presented efficiently to MHC class 
II-restricted T cells (39). The mechanism of retention in the 
ER for these proteins is thought to be through retrieval from 
a post-ER compartment (34).  This could explain how pro- 
teins with ER retention signals gain access to the MHC class 
II processing compartment, i.e., they reach an intermediate 
compartment or the c/s-Golgi  compartment before capture 
and retrieval back to the ER. Alternatively, low levels of es- 
cape through these retention sequences are likely sufficient 
for antigen presentation,  as seen with our HA-EEKKMP 
mutant. 
The findings reported here suggest that there is a mecha- 
nism for directing proteins from an early compartment in 
the secretory pathway to the late endosome/lysosome, where 
fragmentation of the protein and subsequent MHC class II 
charging  can  occur.  This  may be  a  specific  pathway for 
shunting proteins normally retained in early secretory com- 
partments, e.g., ER enzymes, chaperones, etc., to the lyso- 
some. This shunt mechanism does not require protein transit 
through  the medial  or trans-Golgi compartment.  Such a 
pathway might be crucial during development of the T lym- 
phocyte repertoire to provide peptide fragments of these in- 
tracellular proteins for T  lymphocyte-negative selection in 
the thymus. This pathway would therefore provide a mecha- 
nism for establishing CD4 + T  cell tolerance to these self- 
proteins. Alternatively, these early secretory compartment pro- 
teins,  as well as viral proteins like HA, could gain access to 
the lysosome via an ER-associated autophagocytic process on- 
going in APC.  Although to date we have been unable to 
specifically inhibit presentation of wt or mutant HA using 
inhibitors of autophagy (42) (D. J.  Kittlesen, unpublished 
observations),  autophagy could also account for the processing 
and presentation of the HA gene products described in this 
and other reports. 
Peptides observed from proteolysis in the endosome, ER, 
and cytosol may all contribute to the array of antigenic frag- 
ments displayed by MHC class II molecules on the surface 
of APC.  Our findings reinforce the view that  the endo- 
some/lysosome is a primary site of antigen processing and 
presentation to CD4 + T  cells even for proteins retained in 
early compartments of the secretory pathway. The relative 
importance of cytosol,  ER,  and  endosome as  sources of 
processed peptides for self- and non-self discrimination, and 
foreign antigen presentation in APC in vivo, remains to be 
1028  Hemagglutinin  Recognition by CD4 § Cells determined. Recent advances in the isolation and character- 
ization of processed peptide fragments associated with MHC 
class II molecules (43) should provide a framework for defining 
the contribution of these processing compartments to the 
formation of the peptide pool associated  with MHC class 
II molecules. 
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